Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


1424 - Tumour necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma (STS)


11 Sep 2017




Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Soft Tissue Sarcomas


Jeremy Lewin


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


J. Lewin, S. Salah, E. Amir, A.R.A. Razak

Author affiliations

  • Department Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, M5G2M9 - Toronto/CA


Abstract 1424


Tumour necrosis following chemotherapy is prognostic in bone sarcoma, but remains undefined in STS.


We searched MEDLINE, MEDLINE in progress, EMBASE and Cochrane to identify studies that investigated neoadjuvant therapy in STS. Eligible studies were required to have data on survival outcomes based on tumor necrosis in the resected specimen, or provided individual patient data. Hazard ratios (HR) for relapse free (RFS) and overall survival (OS) as well as odds ratios (OR) for recurrence at 3 years and for death at 5 years were pooled in a random effect meta-analysis. Association between patient characteristics and attainment of ≥ 90% necrosis were explored with logistic regression.


21 studies comprising 1644 patients were included in this analysis. Location of the tumor included the extremities in the majority (n = 1459; 89%). Induction regimens included chemotherapy/radiation (n = 813; 49%), chemotherapy alone (n = 418; 25%), chemotherapy/caffeine (n = 81; 5%), radiotherapy alone (n = 78; 5%), isolated limb perfusion (ILP) with (n = 28; 2%) or without radiation (n = 208; 13%), and targeted therapy/radiotherapy (n = 18; 1%). Utilizing a cut-off of 90%, patients with ≥ 90% tumour necrosis had significantly reduced risk of recurrence at 3 years (OR0.30; 95% CI: 0.20-0.44; p 


Tumour necrosis ≥ 90% following neoadjuvant therapy is associated with reduced recurrence risk and improved overall survival in patients with STS.

Clinical trial identification

Legal entity responsible for the study

Princess Margaret Cancer Centre




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.